Voriconazole And Anidulafungin Combination For Invasive Aspergillosis In Pediatric Subjects

A Prospective, Randomized Trial Comparing The Safety, Tolerability, And Efficacy Of Voriconazole And Anidulafungin In Combination To That Of Voriconazole Alone When Used For Primary Therapy Of Invasive Aspergillosis in Pediatric Subjects Aged 2 to 17 Years

This study aims to compare the safety, tolerability, and efficacy of voriconazole and anidulafungin in combination versus voriconazole alone in pediatric subjects aged 2 to 17 years with invasive aspergillosis.

Inclusion Criteria:

• Diagnosis of proven, probable, or possible invasive aspergillosis.
• Hematologic malignancy or allogeneic hematopoetic stem cell transplant.

Exclusion Criteria:

• Sarcoidosis, aspergilloma, or allergic bronchopulmonary aspergillosis.
• Chronic invasive aspergillosis.
• Receipt of antifungal treatment for more than 96 hours.
• Severe liver dysfunction.